Zymeworks Q4 Earnings Call Highlights

The company also reported regulatory approvals during the quarter for zanidatamab monotherapy in Canada and the United Kingdom for second-line biliary tract cancer. Galbraith framed the broader zanidatamab program as a foundation for future milestone and royalty streams. He said Zymeworks expects the program could translate into regulatory milestone payments for global approvals in GEA of up to $440 million, plus an additional $89 million collectively from Jazz and BeiGene upon approval in a third indicatio ...